🇺🇸 BBI608 in United States

31 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Anaemia — 7 reports (22.58%)
  2. Abdominal Pain — 4 reports (12.9%)
  3. Diarrhoea — 4 reports (12.9%)
  4. Pneumonia — 3 reports (9.68%)
  5. Thrombocytopenia — 3 reports (9.68%)
  6. Acute Kidney Injury — 2 reports (6.45%)
  7. Cholestasis — 2 reports (6.45%)
  8. Chronic Obstructive Pulmonary Disease — 2 reports (6.45%)
  9. Clostridium Difficile Infection — 2 reports (6.45%)
  10. Dyspnoea — 2 reports (6.45%)

Source database →

Other Oncology approved in United States

Frequently asked questions

Is BBI608 approved in United States?

BBI608 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for BBI608 in United States?

NCIC Clinical Trials Group is the originator. The local marketing authorisation holder may differ — check the official source linked above.